Recent Updates
Recently added Catalysts
VTGN

CORPORATE PRESENTATION Untitled Document

Thursday, March 14, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CORPORATE PRESENTATION Untitled Document

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
AV-101
Phase 1 · Healthy

Full Press Release Details

CORPORATE PRESENTATION Untitled Document.
ShareAdd on Google
Tags: VTGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 14, 2019

Biotech snapshot

Cash runway
$32M liquidity · $5M/mo burn
~6 mo
Medium dilution risk
Lead asset
AV-101Phase 1
Healthy →